ArticleDiscover oncology2025
Systematic network pharmacology and experimental validation reveal anti-glioma mechanisms of ganoderma lucidum via multi-target regulation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioma is the most common and lethal primary brain tumor with limited therapeutic options and poor prognosis. Traditional Chinese medicine (TCM) offers a promising avenue for discovering multi-target agents against complex diseases. Ganoderma lucidum (Lingzhi), a well-known medicinal fungus, has shown anti-tumor effects in several malignancies, but its molecular mechanisms in glioma remain largely unclear.
methodsWe employed a network pharmacology approach to investigate the active compounds and potential targets of Ganoderma against glioma. Public databases including TCMSP, SwissTargetPrediction, GeneCards, and DisGeNET were used to identify active ingredients and intersecting disease-related targets. GO and KEGG enrichment analyses were performed to explore underlying biological functions and pathways. Protein-protein interaction (PPI) networks were constructed to identify hub genes. Expression, prognostic, and diagnostic relevance of the core targets were validated using TCGA and HPA datasets. Molecular docking was conducted to assess binding affinity between key compounds and targets. Furthermore, in vitro experiments including CCK-8, colony formation, Transwell invasion, and wound healing assays were performed to validate the anti-glioma effects of Beta-Sitosterol, a representative active compound of Ganoderma.
resultsA total of 16 active compounds and 86 glioma-related intersecting targets were identified. Functional enrichment revealed significant involvement in steroid metabolism, GPCR signaling, oxidoreductase activity, and neuroactive ligand-receptor interactions. Seven hub genes (CASP3, PTGS2, HIF1A, BCL2, ESR1, MDM2, and PPARG) were identified based on PPI network analysis. Expression validation and ROC curve analysis confirmed their clinical relevance. Molecular docking demonstrated strong binding affinities between Beta-Sitosterol and key targets such as CASP3 and PTGS2. Experimental assays showed that Beta-Sitosterol inhibited cell viability (IC50 = 24.84 µM), colony formation, invasion, and migration in U87MG glioma cells.
conclusionThis study reveals the multi-target, multi-pathway mechanisms by which Ganoderma may exert therapeutic effects against glioma. Beta-Sitosterol is a promising active compound with significant anti-glioma potential, providing a scientific basis for the development of novel complementary therapies from traditional medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.